NCT05619861

CAR-T Cells in the Treatment of Malignant Hematological Tumors

Clinical Study of CAR-T Technique in the Treatment of Recurrent and Refractory Hematopoietic and Lymphatic Tumor

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Hebei Senlang Biotechnology Inc., Ltd. · Industry
• Sex: All
• Age: 14 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors

Detailed description

Main research objective: To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors. Secondary research objective: To investigate the efficacy and cytodynamic characteristics of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors

Conditions

• Lymphoma, B-Cell
• Leukemia, B-cell
• Leukemia, T-Cell
• Multiple Myeloma

Interventions

Type	Name	Description
BIOLOGICAL	CAR-T	Patients will receive CAR-T treatment

Timeline

• Start date: 2020-04-27
• Primary completion: 2023-01-26
• Completion: 2023-12-26
• First posted: 2022-11-17
• Last updated: 2022-11-17

Locations

1 site across 1 country: China